ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
1
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
1
U.S. (TOLL FREE)
+1 (315) 215-3225
Global C-MET & HGF Inhibitors Market Research Report 2025
Published Date: August 2025
|
Report Code: QYRE-Auto-29T8979
Home | Market Reports | Health| Pharmacy| Drugs & Medications
Global C MET HGF Inhibitors Market Outlook 2022
BUY CHAPTERS

Global C-MET & HGF Inhibitors Market Research Report 2025

Code: QYRE-Auto-29T8979
Report
August 2025
Pages:83
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Exelixis Inc
Ipsen S A
Pfizer Inc
Novartis
Takeda
Takeda Pharmaceutical

C-MET & HGF Inhibitors Market Size

The global market for C-MET & HGF Inhibitors was valued at US$ 3480 million in the year 2024 and is projected to reach a revised size of US$ 10713 million by 2031, growing at a CAGR of 17.5% during the forecast period.

C-MET & HGF Inhibitors Market

C-MET & HGF Inhibitors Market

The 2025 U.S. tariff policies introduce profound uncertainty into the global economic landscape. This report critically examines the implications of recent tariff adjustments and international strategic countermeasures on C-MET & HGF Inhibitors competitive dynamics, regional economic interdependencies, and supply chain reconfigurations.
C-MET & HGF inhibitors are a class of targeted therapies designed to inhibit the aberrant activation of the hepatocyte growth factor (HGF) and its receptor c-MET signaling pathway. This axis is implicated in tumorigenesis processes such as proliferation, invasion, angiogenesis, and metastasis, especially in cancers such as hepatocellular carcinoma, lung cancer, gastric cancer, and renal cancer. The inhibitors include small-molecule tyrosine kinase inhibitors (TKIs) and monoclonal antibodies. In recent years, they have become a key focus in oncology drug development. Drugs such as Capmatinib and Tepotinib, approved by the FDA, are accelerating market expansion with demonstrated clinical efficacy and safety. In 2024, global C-MET & HGF Inhibitors production reached approximately 24 million unit, with an average global market price of around US$ 145/unit.
The abnormal activation or overexpression of the c-MET/HGF signaling pathway in multiple malignancies provides a clear target for precision oncology. As revealed in annual reports from Pfizer and Novartis, several approved C-MET inhibitors have achieved rapid commercialization, especially in late-stage NSCLC. With the expanding global oncology market and increasing adoption of individualized treatment protocols, C-MET & HGF inhibitors possess significant potential for indication expansion. The growing availability of molecular diagnostics, such as RNA sequencing, further accelerates the identification of C-MET-positive patients, boosting treatment penetration.
Despite promising clinical outcomes, C-MET & HGF inhibitors face challenges including inconsistent efficacy, complex resistance mechanisms, and adverse event management. Some early candidates have underperformed in Phase III trials or faced setbacks due to the lack of standardized biomarker-based patient selection. Regulatory pressures are mounting worldwide, demanding robust real-world evidence for safety and efficacy, thus increasing development timelines and costs.
There is growing clinical acceptance of precision-targeted therapies, integrating C-MET inhibitors into multi-line treatment regimens. According to IQVIA and FDA data, numerous global clinical trials are exploring combination therapies involving C-MET inhibitors and immune checkpoint inhibitors. In China, Korea, and other markets, reimbursement policy improvements and the rise of local biotech players are expected to significantly accelerate market penetration in the coming years.

Report Scope

This report aims to provide a comprehensive presentation of the global market for C-MET & HGF Inhibitors, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding C-MET & HGF Inhibitors.
The C-MET & HGF Inhibitors market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global C-MET & HGF Inhibitors market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the C-MET & HGF Inhibitors manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of C-MET & HGF Inhibitors Market Report

Report Metric Details
Report Name C-MET & HGF Inhibitors Market
Accounted market size in year US$ 3480 million
Forecasted market size in 2031 US$ 10713 million
CAGR 17.5%
Base Year year
Forecasted years 2025 - 2031
Segment by Type
  • Cabozantinib
  • Crizotinib
  • Tepotinib
  • Others
Segment by Application
  • Hospital
  • Drug Store
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company Exelixis, Ipsen, Pfizer, Novartis, Takeda, Merck KGaA, Takeda Pharmaceutical
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Detailed analysis of C-MET & HGF Inhibitors manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Sales, revenue of C-MET & HGF Inhibitors in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 9: The main points and conclusions of the report.

FAQ for this report

How fast is C-MET & HGF Inhibitors Market growing?

Ans: The C-MET & HGF Inhibitors Market witnessing a CAGR of 17.5% during the forecast period 2025-2031.

What is the C-MET & HGF Inhibitors Market size in 2031?

Ans: The C-MET & HGF Inhibitors Market size in 2031 will be US$ 10713 million.

Who are the main players in the C-MET & HGF Inhibitors Market report?

Ans: The main players in the C-MET & HGF Inhibitors Market are Exelixis, Ipsen, Pfizer, Novartis, Takeda, Merck KGaA, Takeda Pharmaceutical

What are the Application segmentation covered in the C-MET & HGF Inhibitors Market report?

Ans: The Applications covered in the C-MET & HGF Inhibitors Market report are Hospital, Drug Store

What are the Type segmentation covered in the C-MET & HGF Inhibitors Market report?

Ans: The Types covered in the C-MET & HGF Inhibitors Market report are Cabozantinib, Crizotinib, Tepotinib, Others

1 C-MET & HGF Inhibitors Market Overview
1.1 Product Definition
1.2 C-MET & HGF Inhibitors by Type
1.2.1 Global C-MET & HGF Inhibitors Market Value Comparison by Type (2024 VS 2031)
1.2.2 Cabozantinib
1.2.3 Crizotinib
1.2.4 Tepotinib
1.2.5 Others
1.3 C-MET & HGF Inhibitors by Application
1.3.1 Global C-MET & HGF Inhibitors Market Value by Application (2024 VS 2031)
1.3.2 Hospital
1.3.3 Drug Store
1.4 Global C-MET & HGF Inhibitors Market Size Estimates and Forecasts
1.4.1 Global C-MET & HGF Inhibitors Revenue 2020-2031
1.4.2 Global C-MET & HGF Inhibitors Sales 2020-2031
1.4.3 Global C-MET & HGF Inhibitors Market Average Price (2020-2031)
1.5 Assumptions and Limitations
2 C-MET & HGF Inhibitors Market Competition by Manufacturers
2.1 Global C-MET & HGF Inhibitors Sales Market Share by Manufacturers (2020-2025)
2.2 Global C-MET & HGF Inhibitors Revenue Market Share by Manufacturers (2020-2025)
2.3 Global C-MET & HGF Inhibitors Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of C-MET & HGF Inhibitors, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of C-MET & HGF Inhibitors, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of C-MET & HGF Inhibitors, Product Type & Application
2.7 Global Key Manufacturers of C-MET & HGF Inhibitors, Date of Enter into This Industry
2.8 Global C-MET & HGF Inhibitors Market Competitive Situation and Trends
2.8.1 Global C-MET & HGF Inhibitors Market Concentration Rate
2.8.2 The Global 5 and 10 Largest C-MET & HGF Inhibitors Players Market Share by Revenue
2.8.3 Global C-MET & HGF Inhibitors Company Type and Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global C-MET & HGF Inhibitors Market Scenario by Region
3.1 Global C-MET & HGF Inhibitors Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global C-MET & HGF Inhibitors Sales by Region: 2020-2031
3.2.1 Global C-MET & HGF Inhibitors Sales by Region: 2020-2025
3.2.2 Global C-MET & HGF Inhibitors Sales by Region: 2026-2031
3.3 Global C-MET & HGF Inhibitors Revenue by Region: 2020-2031
3.3.1 Global C-MET & HGF Inhibitors Revenue by Region: 2020-2025
3.3.2 Global C-MET & HGF Inhibitors Revenue by Region: 2026-2031
3.4 North America C-MET & HGF Inhibitors Market Facts & Figures by Country
3.4.1 North America C-MET & HGF Inhibitors Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America C-MET & HGF Inhibitors Sales by Country (2020-2031)
3.4.3 North America C-MET & HGF Inhibitors Revenue by Country (2020-2031)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe C-MET & HGF Inhibitors Market Facts & Figures by Country
3.5.1 Europe C-MET & HGF Inhibitors Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe C-MET & HGF Inhibitors Sales by Country (2020-2031)
3.5.3 Europe C-MET & HGF Inhibitors Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific C-MET & HGF Inhibitors Market Facts & Figures by Region
3.6.1 Asia Pacific C-MET & HGF Inhibitors Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific C-MET & HGF Inhibitors Sales by Region (2020-2031)
3.6.3 Asia Pacific C-MET & HGF Inhibitors Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America C-MET & HGF Inhibitors Market Facts & Figures by Country
3.7.1 Latin America C-MET & HGF Inhibitors Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America C-MET & HGF Inhibitors Sales by Country (2020-2031)
3.7.3 Latin America C-MET & HGF Inhibitors Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa C-MET & HGF Inhibitors Market Facts & Figures by Country
3.8.1 Middle East and Africa C-MET & HGF Inhibitors Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa C-MET & HGF Inhibitors Sales by Country (2020-2031)
3.8.3 Middle East and Africa C-MET & HGF Inhibitors Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global C-MET & HGF Inhibitors Sales by Type (2020-2031)
4.1.1 Global C-MET & HGF Inhibitors Sales by Type (2020-2025)
4.1.2 Global C-MET & HGF Inhibitors Sales by Type (2026-2031)
4.1.3 Global C-MET & HGF Inhibitors Sales Market Share by Type (2020-2031)
4.2 Global C-MET & HGF Inhibitors Revenue by Type (2020-2031)
4.2.1 Global C-MET & HGF Inhibitors Revenue by Type (2020-2025)
4.2.2 Global C-MET & HGF Inhibitors Revenue by Type (2026-2031)
4.2.3 Global C-MET & HGF Inhibitors Revenue Market Share by Type (2020-2031)
4.3 Global C-MET & HGF Inhibitors Price by Type (2020-2031)
5 Segment by Application
5.1 Global C-MET & HGF Inhibitors Sales by Application (2020-2031)
5.1.1 Global C-MET & HGF Inhibitors Sales by Application (2020-2025)
5.1.2 Global C-MET & HGF Inhibitors Sales by Application (2026-2031)
5.1.3 Global C-MET & HGF Inhibitors Sales Market Share by Application (2020-2031)
5.2 Global C-MET & HGF Inhibitors Revenue by Application (2020-2031)
5.2.1 Global C-MET & HGF Inhibitors Revenue by Application (2020-2025)
5.2.2 Global C-MET & HGF Inhibitors Revenue by Application (2026-2031)
5.2.3 Global C-MET & HGF Inhibitors Revenue Market Share by Application (2020-2031)
5.3 Global C-MET & HGF Inhibitors Price by Application (2020-2031)
6 Key Companies Profiled
6.1 Exelixis
6.1.1 Exelixis Company Information
6.1.2 Exelixis Description and Business Overview
6.1.3 Exelixis C-MET & HGF Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Exelixis C-MET & HGF Inhibitors Product Portfolio
6.1.5 Exelixis Recent Developments/Updates
6.2 Ipsen
6.2.1 Ipsen Company Information
6.2.2 Ipsen Description and Business Overview
6.2.3 Ipsen C-MET & HGF Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Ipsen C-MET & HGF Inhibitors Product Portfolio
6.2.5 Ipsen Recent Developments/Updates
6.3 Pfizer
6.3.1 Pfizer Company Information
6.3.2 Pfizer Description and Business Overview
6.3.3 Pfizer C-MET & HGF Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.3.4 Pfizer C-MET & HGF Inhibitors Product Portfolio
6.3.5 Pfizer Recent Developments/Updates
6.4 Novartis
6.4.1 Novartis Company Information
6.4.2 Novartis Description and Business Overview
6.4.3 Novartis C-MET & HGF Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Novartis C-MET & HGF Inhibitors Product Portfolio
6.4.5 Novartis Recent Developments/Updates
6.5 Takeda
6.5.1 Takeda Company Information
6.5.2 Takeda Description and Business Overview
6.5.3 Takeda C-MET & HGF Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.5.4 Takeda C-MET & HGF Inhibitors Product Portfolio
6.5.5 Takeda Recent Developments/Updates
6.6 Merck KGaA
6.6.1 Merck KGaA Company Information
6.6.2 Merck KGaA Description and Business Overview
6.6.3 Merck KGaA C-MET & HGF Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.6.4 Merck KGaA C-MET & HGF Inhibitors Product Portfolio
6.6.5 Merck KGaA Recent Developments/Updates
6.7 Takeda Pharmaceutical
6.7.1 Takeda Pharmaceutical Company Information
6.7.2 Takeda Pharmaceutical Description and Business Overview
6.7.3 Takeda Pharmaceutical C-MET & HGF Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.7.4 Takeda Pharmaceutical C-MET & HGF Inhibitors Product Portfolio
6.7.5 Takeda Pharmaceutical Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 C-MET & HGF Inhibitors Industry Chain Analysis
7.2 C-MET & HGF Inhibitors Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 C-MET & HGF Inhibitors Production Mode & Process Analysis
7.4 C-MET & HGF Inhibitors Sales and Marketing
7.4.1 C-MET & HGF Inhibitors Sales Channels
7.4.2 C-MET & HGF Inhibitors Distributors
7.5 C-MET & HGF Inhibitors Customer Analysis
8 C-MET & HGF Inhibitors Market Dynamics
8.1 C-MET & HGF Inhibitors Industry Trends
8.2 C-MET & HGF Inhibitors Market Drivers
8.3 C-MET & HGF Inhibitors Market Challenges
8.4 C-MET & HGF Inhibitors Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
FEATURED COMPANIES
Exelixis Inc
Ipsen S A
Pfizer Inc
Novartis
Takeda
Takeda Pharmaceutical
List of Tables
 Table 1. Global C-MET & HGF Inhibitors Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
 Table 2. Global C-MET & HGF Inhibitors Market Value by Application (2024 VS 2031) & (US$ Million)
 Table 3. Global C-MET & HGF Inhibitors Market Competitive Situation by Manufacturers in 2024
 Table 4. Global C-MET & HGF Inhibitors Sales (K Units) of Key Manufacturers (2020-2025)
 Table 5. Global C-MET & HGF Inhibitors Sales Market Share by Manufacturers (2020-2025)
 Table 6. Global C-MET & HGF Inhibitors Revenue (US$ Million) by Manufacturers (2020-2025)
 Table 7. Global C-MET & HGF Inhibitors Revenue Share by Manufacturers (2020-2025)
 Table 8. Global Market C-MET & HGF Inhibitors Average Price (US$/Unit) of Key Manufacturers (2020-2025)
 Table 9. Global Key Players of C-MET & HGF Inhibitors, Industry Ranking, 2022 VS 2023 VS 2024
 Table 10. Global Key Manufacturers of C-MET & HGF Inhibitors, Manufacturing Sites & Headquarters
 Table 11. Global Key Manufacturers of C-MET & HGF Inhibitors, Product Type & Application
 Table 12. Global Key Manufacturers of C-MET & HGF Inhibitors, Date of Enter into This Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global C-MET & HGF Inhibitors by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in C-MET & HGF Inhibitors as of 2024)
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global C-MET & HGF Inhibitors Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 17. Global C-MET & HGF Inhibitors Sales by Region (2020-2025) & (K Units)
 Table 18. Global C-MET & HGF Inhibitors Sales Market Share by Region (2020-2025)
 Table 19. Global C-MET & HGF Inhibitors Sales by Region (2026-2031) & (K Units)
 Table 20. Global C-MET & HGF Inhibitors Sales Market Share by Region (2026-2031)
 Table 21. Global C-MET & HGF Inhibitors Revenue by Region (2020-2025) & (US$ Million)
 Table 22. Global C-MET & HGF Inhibitors Revenue Market Share by Region (2020-2025)
 Table 23. Global C-MET & HGF Inhibitors Revenue by Region (2026-2031) & (US$ Million)
 Table 24. Global C-MET & HGF Inhibitors Revenue Market Share by Region (2026-2031)
 Table 25. North America C-MET & HGF Inhibitors Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 26. North America C-MET & HGF Inhibitors Sales by Country (2020-2025) & (K Units)
 Table 27. North America C-MET & HGF Inhibitors Sales by Country (2026-2031) & (K Units)
 Table 28. North America C-MET & HGF Inhibitors Revenue by Country (2020-2025) & (US$ Million)
 Table 29. North America C-MET & HGF Inhibitors Revenue by Country (2026-2031) & (US$ Million)
 Table 30. Europe C-MET & HGF Inhibitors Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 31. Europe C-MET & HGF Inhibitors Sales by Country (2020-2025) & (K Units)
 Table 32. Europe C-MET & HGF Inhibitors Sales by Country (2026-2031) & (K Units)
 Table 33. Europe C-MET & HGF Inhibitors Revenue by Country (2020-2025) & (US$ Million)
 Table 34. Europe C-MET & HGF Inhibitors Revenue by Country (2026-2031) & (US$ Million)
 Table 35. Asia Pacific C-MET & HGF Inhibitors Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 36. Asia Pacific C-MET & HGF Inhibitors Sales by Region (2020-2025) & (K Units)
 Table 37. Asia Pacific C-MET & HGF Inhibitors Sales by Region (2026-2031) & (K Units)
 Table 38. Asia Pacific C-MET & HGF Inhibitors Revenue by Region (2020-2025) & (US$ Million)
 Table 39. Asia Pacific C-MET & HGF Inhibitors Revenue by Region (2026-2031) & (US$ Million)
 Table 40. Latin America C-MET & HGF Inhibitors Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 41. Latin America C-MET & HGF Inhibitors Sales by Country (2020-2025) & (K Units)
 Table 42. Latin America C-MET & HGF Inhibitors Sales by Country (2026-2031) & (K Units)
 Table 43. Latin America C-MET & HGF Inhibitors Revenue by Country (2020-2025) & (US$ Million)
 Table 44. Latin America C-MET & HGF Inhibitors Revenue by Country (2026-2031) & (US$ Million)
 Table 45. Middle East and Africa C-MET & HGF Inhibitors Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 46. Middle East and Africa C-MET & HGF Inhibitors Sales by Country (2020-2025) & (K Units)
 Table 47. Middle East and Africa C-MET & HGF Inhibitors Sales by Country (2026-2031) & (K Units)
 Table 48. Middle East and Africa C-MET & HGF Inhibitors Revenue by Country (2020-2025) & (US$ Million)
 Table 49. Middle East and Africa C-MET & HGF Inhibitors Revenue by Country (2026-2031) & (US$ Million)
 Table 50. Global C-MET & HGF Inhibitors Sales (K Units) by Type (2020-2025)
 Table 51. Global C-MET & HGF Inhibitors Sales (K Units) by Type (2026-2031)
 Table 52. Global C-MET & HGF Inhibitors Sales Market Share by Type (2020-2025)
 Table 53. Global C-MET & HGF Inhibitors Sales Market Share by Type (2026-2031)
 Table 54. Global C-MET & HGF Inhibitors Revenue (US$ Million) by Type (2020-2025)
 Table 55. Global C-MET & HGF Inhibitors Revenue (US$ Million) by Type (2026-2031)
 Table 56. Global C-MET & HGF Inhibitors Revenue Market Share by Type (2020-2025)
 Table 57. Global C-MET & HGF Inhibitors Revenue Market Share by Type (2026-2031)
 Table 58. Global C-MET & HGF Inhibitors Price (US$/Unit) by Type (2020-2025)
 Table 59. Global C-MET & HGF Inhibitors Price (US$/Unit) by Type (2026-2031)
 Table 60. Global C-MET & HGF Inhibitors Sales (K Units) by Application (2020-2025)
 Table 61. Global C-MET & HGF Inhibitors Sales (K Units) by Application (2026-2031)
 Table 62. Global C-MET & HGF Inhibitors Sales Market Share by Application (2020-2025)
 Table 63. Global C-MET & HGF Inhibitors Sales Market Share by Application (2026-2031)
 Table 64. Global C-MET & HGF Inhibitors Revenue (US$ Million) by Application (2020-2025)
 Table 65. Global C-MET & HGF Inhibitors Revenue (US$ Million) by Application (2026-2031)
 Table 66. Global C-MET & HGF Inhibitors Revenue Market Share by Application (2020-2025)
 Table 67. Global C-MET & HGF Inhibitors Revenue Market Share by Application (2026-2031)
 Table 68. Global C-MET & HGF Inhibitors Price (US$/Unit) by Application (2020-2025)
 Table 69. Global C-MET & HGF Inhibitors Price (US$/Unit) by Application (2026-2031)
 Table 70. Exelixis Company Information
 Table 71. Exelixis Description and Business Overview
 Table 72. Exelixis C-MET & HGF Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 73. Exelixis C-MET & HGF Inhibitors Product
 Table 74. Exelixis Recent Developments/Updates
 Table 75. Ipsen Company Information
 Table 76. Ipsen Description and Business Overview
 Table 77. Ipsen C-MET & HGF Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 78. Ipsen C-MET & HGF Inhibitors Product
 Table 79. Ipsen Recent Developments/Updates
 Table 80. Pfizer Company Information
 Table 81. Pfizer Description and Business Overview
 Table 82. Pfizer C-MET & HGF Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 83. Pfizer C-MET & HGF Inhibitors Product
 Table 84. Pfizer Recent Developments/Updates
 Table 85. Novartis Company Information
 Table 86. Novartis Description and Business Overview
 Table 87. Novartis C-MET & HGF Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 88. Novartis C-MET & HGF Inhibitors Product
 Table 89. Novartis Recent Developments/Updates
 Table 90. Takeda Company Information
 Table 91. Takeda Description and Business Overview
 Table 92. Takeda C-MET & HGF Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 93. Takeda C-MET & HGF Inhibitors Product
 Table 94. Takeda Recent Developments/Updates
 Table 95. Merck KGaA Company Information
 Table 96. Merck KGaA Description and Business Overview
 Table 97. Merck KGaA C-MET & HGF Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 98. Merck KGaA C-MET & HGF Inhibitors Product
 Table 99. Merck KGaA Recent Developments/Updates
 Table 100. Takeda Pharmaceutical Company Information
 Table 101. Takeda Pharmaceutical Description and Business Overview
 Table 102. Takeda Pharmaceutical C-MET & HGF Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 103. Takeda Pharmaceutical C-MET & HGF Inhibitors Product
 Table 104. Takeda Pharmaceutical Recent Developments/Updates
 Table 105. Key Raw Materials Lists
 Table 106. Raw Materials Key Suppliers Lists
 Table 107. C-MET & HGF Inhibitors Distributors List
 Table 108. C-MET & HGF Inhibitors Customers List
 Table 109. C-MET & HGF Inhibitors Market Trends
 Table 110. C-MET & HGF Inhibitors Market Drivers
 Table 111. C-MET & HGF Inhibitors Market Challenges
 Table 112. C-MET & HGF Inhibitors Market Restraints
 Table 113. Research Programs/Design for This Report
 Table 114. Key Data Information from Secondary Sources
 Table 115. Key Data Information from Primary Sources
 Table 116. Authors List of This Report


List of Figures
 Figure 1. Product Picture of C-MET & HGF Inhibitors
 Figure 2. Global C-MET & HGF Inhibitors Market Value Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global C-MET & HGF Inhibitors Market Share by Type: 2024 & 2031
 Figure 4. Cabozantinib Product Picture
 Figure 5. Crizotinib Product Picture
 Figure 6. Tepotinib Product Picture
 Figure 7. Others Product Picture
 Figure 8. Global C-MET & HGF Inhibitors Market Value by Application (2020-2031) & (US$ Million)
 Figure 9. Global C-MET & HGF Inhibitors Market Share by Application: 2024 & 2031
 Figure 10. Hospital
 Figure 11. Drug Store
 Figure 12. Global C-MET & HGF Inhibitors Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 13. Global C-MET & HGF Inhibitors Market Size (2020-2031) & (US$ Million)
 Figure 14. Global C-MET & HGF Inhibitors Sales (2020-2031) & (K Units)
 Figure 15. Global C-MET & HGF Inhibitors Average Price (US$/Unit) & (2020-2031)
 Figure 16. C-MET & HGF Inhibitors Report Years Considered
 Figure 17. C-MET & HGF Inhibitors Sales Share by Manufacturers in 2024
 Figure 18. Global C-MET & HGF Inhibitors Revenue Share by Manufacturers in 2024
 Figure 19. Global 5 and 10 Largest C-MET & HGF Inhibitors Players: Market Share by Revenue in C-MET & HGF Inhibitors in 2024
 Figure 20. C-MET & HGF Inhibitors Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
 Figure 21. Global C-MET & HGF Inhibitors Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Figure 22. North America C-MET & HGF Inhibitors Sales Market Share by Country (2020-2031)
 Figure 23. North America C-MET & HGF Inhibitors Revenue Market Share by Country (2020-2031)
 Figure 24. U.S. C-MET & HGF Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 25. Canada C-MET & HGF Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 26. Europe C-MET & HGF Inhibitors Sales Market Share by Country (2020-2031)
 Figure 27. Europe C-MET & HGF Inhibitors Revenue Market Share by Country (2020-2031)
 Figure 28. Germany C-MET & HGF Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 29. France C-MET & HGF Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 30. U.K. C-MET & HGF Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 31. Italy C-MET & HGF Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 32. Russia C-MET & HGF Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 33. Asia Pacific C-MET & HGF Inhibitors Sales Market Share by Region (2020-2031)
 Figure 34. Asia Pacific C-MET & HGF Inhibitors Revenue Market Share by Region (2020-2031)
 Figure 35. China C-MET & HGF Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 36. Japan C-MET & HGF Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 37. South Korea C-MET & HGF Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 38. India C-MET & HGF Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 39. Australia C-MET & HGF Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 40. Taiwan C-MET & HGF Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 41. Indonesia C-MET & HGF Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 42. Thailand C-MET & HGF Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 43. Malaysia C-MET & HGF Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 44. Philippines C-MET & HGF Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 45. Latin America C-MET & HGF Inhibitors Sales Market Share by Country (2020-2031)
 Figure 46. Latin America C-MET & HGF Inhibitors Revenue Market Share by Country (2020-2031)
 Figure 47. Mexico C-MET & HGF Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 48. Brazil C-MET & HGF Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 49. Argentina C-MET & HGF Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 50. Middle East and Africa C-MET & HGF Inhibitors Sales Market Share by Country (2020-2031)
 Figure 51. Middle East and Africa C-MET & HGF Inhibitors Revenue Market Share by Country (2020-2031)
 Figure 52. Turkey C-MET & HGF Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 53. Saudi Arabia C-MET & HGF Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 54. UAE C-MET & HGF Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 55. Global Sales Market Share of C-MET & HGF Inhibitors by Type (2020-2031)
 Figure 56. Global Revenue Market Share of C-MET & HGF Inhibitors by Type (2020-2031)
 Figure 57. Global C-MET & HGF Inhibitors Price (US$/Unit) by Type (2020-2031)
 Figure 58. Global Sales Market Share of C-MET & HGF Inhibitors by Application (2020-2031)
 Figure 59. Global Revenue Market Share of C-MET & HGF Inhibitors by Application (2020-2031)
 Figure 60. Global C-MET & HGF Inhibitors Price (US$/Unit) by Application (2020-2031)
 Figure 61. C-MET & HGF Inhibitors Value Chain
 Figure 62. Channels of Distribution (Direct Vs Distribution)
 Figure 63. Bottom-up and Top-down Approaches for This Report
 Figure 64. Data Triangulation
 Figure 65. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Nano String

SIMILAR REPORTS

Global MET Inhibitor Drugs Market Research Report 2025
Global Single target MET TKIs Market Research Report 2024
Global MET TKIs Market Research Report 2024
Global Multi target MET TKIs Market Research Report 2024
Global VEGF Inhibitors Market Research Report 2024
Global Epidermal Growth Factor Receptor Inhibitors Market Research Report 2024
Global Tyrosine Kinase Inhibitors Market Research Report 2024
Global MEK Inhibitor Market Research Report 2024
Global Hepatocyte Growth Factor HGF Antibody Market Research Report 2024
Global BRAF Inhibitors Market Research Report 2024
Global Pan FGFR Inhibitors Market Research Report 2024
Global Medical FLT3 Inhibitor Market Research Report 2024
Global Kinase Inhibitors For Cancer Treatment Market Research Report 2024
Global Anti VEGF Drugs for Angiogenesis related Disease Market Research Report 2024
mTOR Inhibitors Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global CDK4 6 Inhibitors Market Research Report 2024
Global ALK Inhibitors Market Research Report 2024
Global Small Molecule Multi target Angiogenesis Inhibitor Market Research Report 2024
Global FLT3 Antagonists Market Research Report 2024
Global MEK Inhibitors Market Insights Forecast to 2030

RELATED REPORTS

Global Long-Acting HIV-1 Inhibitors Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-19B19893
Thu Sep 11 00:00:00 UTC 2025

Add to Cart

Global Methylphenidate Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-30B3636
Thu Sep 11 00:00:00 UTC 2025

Add to Cart

Global Soliris Intravenous Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-3H1702
Thu Sep 11 00:00:00 UTC 2025

Add to Cart

Global Mouth Ulcers Drugs Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-13C3384
Wed Sep 10 00:00:00 UTC 2025

Add to Cart

Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions